[Congress] #SNMMI19 Annual Meeting – 22-25 June– California

Web SNMMI2019 

Meet Scott Barksdale during the SNMMI Annual Meeting to explore our multi-modal pharmaco-Imaging and targeted radiotherapy expertise for your preclinical projects.

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational #nuclearmedicine #biomarkers
  • Evaluation of targeted radiotherapy efficacy

Moreover, Oncodesign can help leverage your preclinical targeted  #radiotherapy program!
Our experts can manage a complete  #preclinical targeted radiopharmaceuticals project, including combination studies with  #DNA damage inhibitor or #Immune_checkpoint  #inhibitors!
We offer cutting-edge technology & cross expertise with other therapies and models. .

I fix a meeting!


[Press Release] Oncodesign : 2018 annual results


[Congress] 2nd Annual 3D Tissue Models Oncology - 7-9 May - Boston - USA

2nd Annual 3D Tissue Models Oncology - 7-9 mai - Boston

Phil Kasprzyk, Business Development Manager, will be there to meet you and to discuss about innovative predictive tools for IO combination available at Oncodesign:

- In-vitro / in-vivo pharmacology of immune checkpoint inhibitors
- Translational human reconstituted immune system in cancer models
- Translational cancer biomarkers


I fix a meeting!


[Congress] 2019 77th Annual SID Meeting – 8-11 May – Chicago - USA

77th Annual SID Meeting – 8-11 Mai – Chicago

Scott Barksdale, Business Development Manager, will attend this annual meeting.
This will be a great opportunity to interact with scientists on the latest advances discussed during the conferences.
We will be also pleased to let you know about our new mouse model of colitis induced by anti-CTLA-4 that can mimic the side effects of immunotherapies (diarrhea and colitis).

I fix a meeting

By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.